Cargando…
Targetable Molecular Alterations in the Treatment of Biliary Tract Cancers: An Overview of the Available Treatments
SIMPLE SUMMARY: Biliary tract cancers (BTCs) are rare tumours associated with poor prognosis. In advanced-stage disease, two treatment lines are approved: gemcitabine-cisplatin in combination with checkpoint inhibitors, and 5-FU-oxaliplatin, with a median overall survival of approximately one year....
Autores principales: | Valery, Marine, Vasseur, Damien, Fachinetti, Francesco, Boilève, Alice, Smolenschi, Cristina, Tarabay, Anthony, Antoun, Leony, Perret, Audrey, Fuerea, Alina, Pudlarz, Thomas, Boige, Valérie, Hollebecque, Antoine, Ducreux, Michel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10526255/ https://www.ncbi.nlm.nih.gov/pubmed/37760415 http://dx.doi.org/10.3390/cancers15184446 |
Ejemplares similares
-
Precision Medicine in Pancreatic Ductal Adenocarcinoma: The Impact of Targeted Therapies on Survival of Patients Harboring Actionable Mutations
por: Tarabay, Anthony, et al.
Publicado: (2023) -
Immunotherapy in Advanced Biliary Tract Cancers
por: Boilève, Alice, et al.
Publicado: (2021) -
Immunotherapy and Hepatocellular Cancer: Where Are We Now?
por: Valery, Marine, et al.
Publicado: (2022) -
Molecular targeted therapy of BRAF-mutant colorectal cancer
por: Ducreux, Michel, et al.
Publicado: (2019) -
No evidence for changes in skeletal muscle mass or weight during first-line chemotherapy for metastatic colorectal cancer
por: Antoun, Sami, et al.
Publicado: (2019)